Oramed Completes Phase IIb Oral Insulin Study

 April 6, 2016 | Israeli biomedical company Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that all follow-up visits in the Company’s Phase IIb study of its oral insulin capsule, ORMD-0801, have been completed. The study, of 180 patients with type 2 diabetes, was initiated on June 30, 2015 and conducted at 33 clinical sites in the United States. The study was designed to generate ample data for both safety and efficacy endpoints.  Top-line results are expected later this quarter.  Founded in 2006 and led by CEO Nadav Kidron, Oramed announced in late December the closing of a $50 million + 10% royalties licensing and investment agreement with Hefei Tianhui Incubation of Technologies Co. Ltd. for its oral insulin capsule in China.